Autolus Therapeutics (NASDAQ:AUTL) Trading Down 5.4%

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price dropped 5.4% during mid-day trading on Friday . The stock traded as low as $3.30 and last traded at $3.30. Approximately 1,129,245 shares were traded during trading, a decline of 30% from the average daily volume of 1,602,089 shares. The stock had previously closed at $3.49.

Analyst Upgrades and Downgrades

AUTL has been the subject of several analyst reports. Truist Financial raised their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. Finally, William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.70.

Autolus Therapeutics Price Performance

The company has a 50-day moving average price of $3.96 and a two-hundred day moving average price of $5.28.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Friday, May 17th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.14). The firm had revenue of $10.09 million during the quarter, compared to analysts’ expectations of $50.00 million. During the same period in the previous year, the business posted ($0.23) earnings per share. On average, research analysts predict that Autolus Therapeutics plc will post -0.78 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several large investors have recently made changes to their positions in the company. EWA LLC grew its stake in shares of Autolus Therapeutics by 40.2% in the 4th quarter. EWA LLC now owns 25,678 shares of the company’s stock valued at $155,000 after buying an additional 7,361 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Autolus Therapeutics by 66.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company’s stock valued at $172,000 after buying an additional 10,771 shares during the period. EntryPoint Capital LLC grew its stake in shares of Autolus Therapeutics by 113.6% in the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after buying an additional 11,456 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Autolus Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company’s stock valued at $315,000 after buying an additional 12,387 shares during the period. Finally, Privium Fund Management B.V. grew its stake in shares of Autolus Therapeutics by 43.2% in the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock valued at $319,000 after buying an additional 15,091 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.